APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Epidermal Growth Factor Receptor (EGFR) Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Outlook and Growth Opportunities 2026

Report ID 173988860422 December 2025195 pages

Choose your research edition.

Industry ResearchEpidermal Growth Factor Receptor (EGFR) Inhibitor Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Epidermal Growth Factor Receptor (EGFR) Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Epidermal Growth Factor Receptor (EGFR) Inhibitor market include Novartis AG, Eli Lilly and Co., Amgen Inc., AstraZeneca Plc and F. Hoffmann-La Roche Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Epidermal Growth Factor Receptor (EGFR) Inhibitor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Epidermal Growth Factor Receptor (EGFR) Inhibitor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market.

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Company

Novartis AG

Eli Lilly and Co.

Amgen Inc.

AstraZeneca Plc

F. Hoffmann-La Roche Ltd.

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Type

Colorectal Cancer

Lung Cancer

Breast Cancer

Others

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Application

Clinic

Hospital

Research Institutes and Research Institutions

Other

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Epidermal Growth Factor Receptor (EGFR) Inhibitor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Epidermal Growth Factor Receptor (EGFR) Inhibitor key companies, revenue, market share, and recent developments.

3. To split the Epidermal Growth Factor Receptor (EGFR) Inhibitor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Epidermal Growth Factor Receptor (EGFR) Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Epidermal Growth Factor Receptor (EGFR) Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Epidermal Growth Factor Receptor (EGFR) Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Epidermal Growth Factor Receptor (EGFR) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epidermal Growth Factor Receptor (EGFR) Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Epidermal Growth Factor Receptor (EGFR) Inhibitor industry.

Chapter 3: Detailed analysis of Epidermal Growth Factor Receptor (EGFR) Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Epidermal Growth Factor Receptor (EGFR) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Epidermal Growth Factor Receptor (EGFR) Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends Table 2. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Drivers Table 3. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Opportunities and Challenges Table 4. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Restraints Table 5. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Company Manufacturing Base & Headquarters Table 9. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company, Product Type & Application Table 10. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Colorectal Cancer Table 15. Significant Companies of Lung Cancer Table 16. Significant Companies of Breast Cancer Table 17. Significant Companies of Others Table 18. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type (2021-2026) Table 22. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Clinic Table 24. Significant Companies of Hospital Table 25. Significant Companies of Research Institutes and Research Institutions Table 26. Significant Companies of Other Table 27. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application (2021-2026) Table 31. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application (2027-2032) Table 32. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Region (2021-2026) Table 35. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Region (2027-2032) Table 37. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Market Share by Country (2021-2026) Table 40. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Market Share by Country (2027-2032) Table 42. Novartis AG Company Information Table 43. Novartis AG Business Overview Table 44. Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 46. Novartis AG Recent Development Table 47. Eli Lilly and Co. Company Information Table 48. Eli Lilly and Co. Business Overview Table 49. Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 51. Eli Lilly and Co. Recent Development Table 52. Amgen Inc. Company Information Table 53. Amgen Inc. Business Overview Table 54. Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 56. Amgen Inc. Recent Development Table 57. AstraZeneca Plc Company Information Table 58. AstraZeneca Plc Business Overview Table 59. AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 61. AstraZeneca Plc Recent Development Table 62. F. Hoffmann-La Roche Ltd. Company Information Table 63. F. Hoffmann-La Roche Ltd. Business Overview Table 64. F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 66. F. Hoffmann-La Roche Ltd. Recent Development Table 67. Research Programs/Design for This Report Table 68. Authors List of This Report Table 69. Secondary Sources Table 70. Primary Sources List of Figures Figure 1. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Image Figure 2. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Colorectal Cancer Image Figure 8. Lung Cancer Image Figure 9. Breast Cancer Image Figure 10. Others Image Figure 11. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type (2021-2032) Figure 14. Clinic Image Figure 15. Hospital Image Figure 16. Research Institutes and Research Institutions Image Figure 17. Other Image Figure 18. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application (2021-2032) Figure 21. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 24. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 30. South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Others
Applications
  • Clinic
  • Hospital
  • Research Institutes and Research Institutions
  • Other
Companies covered
  • Novartis AG
  • Eli Lilly and Co.
  • Amgen Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Dynamics
  1. 2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends
  2. 2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Drivers
  3. 2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Opportunities and Challenges
  4. 2.4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Restraints
3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Company
  1. 3.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Ranking (2024-2026)
  4. 3.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Manufacturing Base and Headquarters
  5. 3.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Product Type and Application
  6. 3.6 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Epidermal Growth Factor Receptor (EGFR) Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Type
  1. 4.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Type Introduction
  2. 4.1.1 Colorectal Cancer
  3. 4.1.2 Lung Cancer
  4. 4.1.3 Breast Cancer
  5. 4.1.4 Others
  6. 4.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type
  7. 4.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Type (2021-2032)
  9. 4.2.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type (2021-2032)
5 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Application
  1. 5.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Institutes and Research Institutions
  5. 5.1.4 Other
  6. 5.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application
  7. 5.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Application (2021-2032)
  9. 5.2.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application (2021-2032)
6 Epidermal Growth Factor Receptor (EGFR) Inhibitor Regional Value Analysis
  1. 6.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032)
  7. 6.3.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032)
  10. 6.4.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032)
  16. 6.6.2 South America Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Epidermal Growth Factor Receptor (EGFR) Inhibitor Country-level Value Analysis
  1. 7.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Eli Lilly and Co.
  8. 8.2.1 Eli Lilly and Co. Company Information
  9. 8.2.2 Eli Lilly and Co. Business Overview
  10. 8.2.3 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  12. 8.2.5 Eli Lilly and Co. Recent Developments
  13. 8.3 Amgen Inc.
  14. 8.3.1 Amgen Inc. Company Information
  15. 8.3.2 Amgen Inc. Business Overview
  16. 8.3.3 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  18. 8.3.5 Amgen Inc. Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 F. Hoffmann-La Roche Ltd.
  26. 8.5.1 F. Hoffmann-La Roche Ltd. Company Information
  27. 8.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst